Concise Review: Stem Cells in Pancreatic Cancer: From Concept to Translation

Stem Cells

Volumn 33, Issue 10, 2015, Pages 2893-2902

  Raj, Deepak ^a   Aicher, Alexandra ^a   Heeschen, Christopher ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer stem cells; Pancreatic ductal adenocarcinoma; Stromal cells; Therapeutics intervention

Indexed keywords

ANTINEOPLASTIC AGENT; AZITHROMYCIN; CC 90002; CHLOROQUINE; CURCUMIN; ERLOTINIB; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; MOCETINOSTAT; MONOCLONAL ANTIBODY; NAPABUCASIN; NATURAL PRODUCT; PATIDEGIB; PEGPH 20; RESVERATROL; SALINOMYCIN; SONIC HEDGEHOG PROTEIN; SULFORAPHANE; UNCLASSIFIED DRUG; VISMODEGIB; VITAMIN D; VORINOSTAT;

ADOPTIVE IMMUNOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL FUNCTION; CELL HETEROGENEITY; CELL RENEWAL; CIRCULATING TUMOR CELL; CLINICAL TRIAL (TOPIC); DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IN VIVO STUDY; LONG TERM SURVIVAL; METASTASIS; NONHUMAN; PANCREAS CANCER; PHENOTYPE; REVIEW; SIGNAL TRANSDUCTION; STROMA; TUMOR MICROENVIRONMENT; ANIMAL; CELL PROLIFERATION; DRUG RESISTANCE; DRUG SCREENING; GENETICS; PANCREATIC NEOPLASMS; PATHOLOGY;

ANIMALS; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84942374002     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2114     Document Type: Review

References (111)

1. Siegel R, Ma J, Zou Z, et al., Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Hidalgo M,. Pancreatic cancer. N Engl J Med 2010; 362: 1605-1617.
3. Von Hoff DD, Ervin T, Arena FP, et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-1703.
4. Conroy T, Desseigne F, Ychou M, et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
5. Ryan DP, Hong TS, Bardeesy N,. Pancreatic adenocarcinoma. N Engl J Med 2014; 371: 2140-2141.
6. Rahib L, Smith BD, Aizenberg R, et al., Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-2921.
7. Visvader JE, Lindeman GJ,. Cancer stem cells: Current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
8. Kreso A, Dick JE,. Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275-291.
9. Li C, Wu JJ, Hynes M, et al., c-Met is a marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 2011; 141: 2218-2227.
10. Li C, Heidt DG, Dalerba P, et al., Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-1037.
11. Miranda-Lorenzo I, Dorado J, Lonardo E, et al., Intracellular autofluorescence: A biomarker for epithelial cancer stem cells. Nat Methods 2014; 11: 1161-1169.
12. Hermann PC, Huber SL, Herrler T, et al., Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323.
13. Ishizawa K, Rasheed ZA, Karisch R, et al., Tumor-initiating cells are rare in many human tumors. Cell Stem Cell 2010; 7: 279-282.
14. Jimeno A, Feldmann G, Suarez-Gauthier A, et al., A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009; 8: 310-314.
15. Rasheed ZA, Yang J, Wang Q, et al., Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst 2010; 102: 340-351.
16. Micalizzi DS, Farabaugh SM, Ford HL,. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia 2010; 15: 117-134.
17. Sainz B, Jr., Martin B, Tatari M, et al., ISG15 is a critical microenvironmental factor for pancreatic cancer stem cells. Cancer Res 2014; 74: 7309-7320.
18. Lonardo E, Frias-Aldeguer J, Hermann PC, et al., Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness. Cell Cycle 2012; 11: 1282-1290.
19. Noman MZ, Messai Y, Carre T, et al., Microenvironmental hypoxia orchestrating the cell stroma cross talk, tumor progression and antitumor response. Crit Rev Immunol 2011; 31: 357-377.
20. Dalerba P, Kalisky T, Sahoo D, et al., Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat Biotechnol 2011; 29: 1120-1127.
21. Merlos-Suarez A, Barriga FM, Jung P, et al., The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-524.
22. Pece S, Tosoni D, Confalonieri S, et al., Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010; 140: 62-73.
23. Sainz B, Jr., Alcala S, Garcia E, et al., Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 2015. pii: gutjnl-2014-308935. doi: 10.1136/gutjnl-2014-308935. [Epub ahead of print]
24. Adikrisna R, Tanaka S, Muramatsu S, et al., Identification of pancreatic cancer stem cells and selective toxicity of chemotherapeutic agents. Gastroenterology 2012; 143: 234-245.
25. Lonardo E, Hermann PC, Heeschen C,. Pancreatic cancer stem cells-Update and future perspectives. Mol Oncol 2010; 4: 431-442.
26. Quintana E, Shackleton M, Sabel MS, et al., Efficient tumour formation by single human melanoma cells. Nature 2008; 456: 593-598.
27. Quintana E, Shackleton M, Foster HR, et al., Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010; 18: 510-523.
28. Boiko AD, Razorenova OV, van de Rijn M, et al., Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 2010; 466: 133-137.
29. Hingorani SR, Wang L, Multani AS, et al., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005; 7: 469-483.
30. Olive KP, Jacobetz MA, Davidson CJ, et al., Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009; 324: 1457-1461.
31. Ischenko I, Petrenko O, Hayman MJ,. Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas. Proc Natl Acad Sci USA 2014; 111: 3466-3471.
32. Bailey JM, Alsina J, Rasheed ZA, et al., DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer. Gastroenterology 2014; 146: 245-256.
33. Li X, Ma Q, Xu Q, et al., SDF-1/CXCR4 signaling induces pancreatic cancer cell invasion and epithelial-mesenchymal transition in vitro through non-canonical activation of Hedgehog pathway. Cancer Lett 2012; 322: 169-176.
34. Pantel K, Alix-Panabieres C,. Real-time liquid biopsy in cancer patients: Fact or fiction? Cancer Res 2013; 73: 6384-6388.
35. Kang Y, Pantel K,. Tumor cell dissemination: Emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23: 573-581.
36. Aceto N, Bardia A, Miyamoto DT, et al., Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158: 1110-1122.
37. de Bono JS, Scher HI, Montgomery RB, et al., Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
38. Cristofanilli M, Budd GT, Ellis MJ, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791.
39. Cohen SJ, Punt CJ, Iannotti N, et al., Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 3213-3221.
40. Deng Y, Zhang Y, Sun S, et al., An integrated microfluidic chip system for single-cell secretion profiling of rare circulating tumor cells. Sci Rep 2014; 4: 7499.
41. Li P, Mao Z, Peng Z, et al., Acoustic separation of circulating tumor cells. Proc Natl Acad Sci USA 2015; 112: 4970-4975.
42. Magbanua MJ, Carey LA, DeLuca A, et al., Circulating tumor cell analysis in metastatic triple-negative breast cancers. Clin Cancer Res 2015; 21: 1098-1105.
43. Baccelli I, Schneeweiss A, Riethdorf S, et al., Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-544.
44. Hodgkinson CL, Morrow CJ, Li Y, et al., Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014; 20: 897-903.
45. Aktas B, Tewes M, Fehm T, et al., Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009; 11: R46.
46. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al., Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012; 14: R15.
47. Chen D, Bhat-Nakshatri P, Goswami C, et al., ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. Cancer Res 2013; 73: 5821-5833.
48. Reuben JM, Lee BN, Gao H, et al., Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24lo cancer stem cell phenotype. Eur J Cancer 2011; 47: 1527-1536.
49. Geng Y, Narasipura S, Seigel GM, et al., Vascular recruitment of human retinoblastoma cells by multi-cellular adhesive interactions with circulating leukocytes. Cell Mol Bioeng 2010; 3: 361-368.
50. Liang SC, Yang CY, Tseng JY, et al., ABCG2 localizes to the nucleus and modulates CDH1 expression in lung cancer cells. Neoplasia 2015; 17: 265-278.
51. Abraham BK, Fritz P, McClellan M, et al., Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005; 11: 1154-1159.
52. Zhang SS, Han ZP, Jing YY, et al., CD133(+)CXCR4(+) colon cancer cells exhibit metastatic potential and predict poor prognosis of patients. BMC Med 2012; 10: 85.
53. Oskarsson T, Batlle E, Massague J,. Metastatic stem cells: Sources, niches, and vital pathways. Cell Stem Cell 2014; 14: 306-321.
54. Kim MY, Oskarsson T, Acharyya S, et al., Tumor self-seeding by circulating cancer cells. Cell 2009; 139: 1315-1326.
55. Malanchi I, Santamaria-Martinez A, Susanto E, et al., Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012; 481: 85-89.
56. Pang R, Law WL, Chu AC, et al., A subpopulation of CD26 + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010; 6: 603-615.
57. Thompson EW, Haviv I,. The social aspects of EMT-MET plasticity. Nat Med 2011; 17: 1048-1049.
58. Yilmaz M, Christofori G,. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 2009; 28: 15-33.
59. Nieto MA,. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013; 342: 1234850.
60. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
61. Polyak K, Weinberg RA,. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273.
62. Liu S, Cong Y, Wang D, et al., Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Reports 2014; 2: 78-91.
63. Chaffer CL, Marjanovic ND, Lee T, et al., Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 2013; 154: 61-74.
64. Hsu YC, Fuchs E,. A family business: Stem cell progeny join the niche to regulate homeostasis. Nat Rev Mol Cell Biol 2012; 13: 103-114.
65. Clevers H, Loh KM, Nusse R,. Stem cell signaling. An integral program for tissue renewal and regeneration: Wnt signaling and stem cell control. Science 2014; 346: 1248012.
66. Hamada S, Masamune A, Takikawa T, et al., Pancreatic stellate cells enhance stem cell-like phenotypes in pancreatic cancer cells. Biochem Biophys Res Commun 2012; 421: 349-354.
67. Kraman M, Bambrough PJ, Arnold JN, et al., Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010; 330: 827-830.
68. Feig C, Jones JO, Kraman M, et al., Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA 2013; 110: 20212-20217.
69. Kim EJ, Sahai V, Abel EV, et al., Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014; 20: 5937-5945.
70. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al., Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014; 25: 719-734.
71. Lonardo E, Hermann PC, Mueller MT, et al., Nodal/Activin signaling drives self-renewal and tumorigenicity of pancreatic cancer stem cells and provides a target for combined drug therapy. Cell Stem Cell 2011; 9: 433-446.
72. Mueller MT, Hermann PC, Witthauer J, et al., Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology 2009; 137: 1102-1113.
73. Hermann PC, Trabulo SM, Sainz B, Jr., et al., Multimodal treatment eliminates cancer stem cells and leads to long-term survival in primary human pancreatic cancer tissue xenografts. PLoS One 2013; 8: e66371.
74. Lonardo E, Cioffi M, Sancho P, et al., Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS One 2013; 8: e76518.
75. Balic A, Sorensen MD, Trabulo SM, et al., Chloroquine targets pancreatic cancer stem cells via inhibition of CXCR4 and hedgehog signaling. Mol Cancer Ther 2014; 13: 1758-1771.
76. Provenzano PP, Cuevas C, Chang AE, et al., Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 2012; 21: 418-429.
77. Jacobetz MA, Chan DS, Neesse A, et al., Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2013; 62: 112-120.
78. Sherman MH, Yu RT, Engle DD, et al., Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014; 159: 80-93.
79. Wong PP, Demircioglu F, Ghazaly E, et al., Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread. Cancer Cell 2015; 27: 123-137.
80. Tavora B, Reynolds LE, Batista S, et al., Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature 2014; 514: 112-116.
81. Burris HA, 3rd, Moore MJ, Andersen J, et al., Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997; 15: 2403-2413.
82. Cioffi M, Trabulo SM, Sanchez-Ripoll Y, et al., The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut 2015. pii: gutjnl-2014-308470. doi: 10.1136/gutjnl-2014-308470. [Epub ahead of print].
83. Xia J, Duan Q, Ahmad A, et al., Genistein inhibits cell growth and induces apoptosis through up-regulation of miR-34a in pancreatic cancer cells. Curr Drug Targets 2012; 13: 1750-1756.
84. Li Y, Rogoff HA, Keates S, et al., Suppression of cancer relapse and metastasis by inhibiting cancer stemness. Proc Natl Acad Sci USA 2015; 112: 1839-1844.
85. Seguin L, Kato S, Franovic A, et al., An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat Cell Biol 2014; 16: 457-468.
86. Bao B, Wang Z, Ali S, et al., Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) 2012; 5: 355-364.
87. Wilmink JW, Kordes S, Zwindeman K, et al., A phase II randomized, placebo controlled study to evaluate the efficacy of the combination of gemcitabine, erlotinib, and metformin in patients with locally advanced or metastatic pancreatic cancer. J Clin Oncol 2014; 32: 4021.
88. Carvalho A, De Celis Ferrari R,. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. J Clin Oncol 2014; 32: e15196.
89. Nalls D, Tang SN, Rodova M, et al., Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 2011; 6: e24099.
90. Meidhof S, Brabletz S, Lehmann W, et al., ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med 2015; 7: 831-847.
91. Hu Y, Fu L,. Targeting cancer stem cells: A new therapy to cure cancer patients. Am J Cancer Res 2012; 2: 340-356.
92. Schenk M, Aykut B, Teske C, et al., Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity. Cancer Lett 2015; 358: 161-169.
93. Lamb R, Ozsvari B, Lisanti CL, et al., Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget 2015; 6: 4569-4584.
94. Viale A, Pettazzoni P, Lyssiotis CA, et al., Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 2014; 514: 628-632.
95. Ali S, Ahmad A, Banerjee S, et al., Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF. Cancer Res 2010; 70: 3606-3617.
96. Bao B, Ali S, Kong D, et al., Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 2011; 6: e17850.
97. Li Y, VandenBoom TG, 2nd, Kong D, et al., Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 2009; 69: 6704-6712.
98. Rausch V, Liu L, Kallifatidis G, et al., Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res 2010; 70: 5004-5013.
99. Persons KS, Eddy VJ, Chadid S, et al., Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells. Anticancer Res 2010; 30: 1875-1880.
100. Schwartz GG, Eads D, Naczki C, et al., 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 2008; 7: 430-436.
101. Bhattacharjee V, Zhou Y, Yen TJ,. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells. Cell Cycle 2014; 13: 3839-3856.
102. Li Z, Jia Z, Gao Y, et al., Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Clin Cancer Res 2015; 21: 844-853.
103. Visus C, Wang Y, Lozano-Leon A, et al., Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8(+) T cells. Clin Cancer Res 2011; 17: 6174-6184.
104. Yin T, Shi P, Gou S, et al., Dendritic cells loaded with pancreatic Cancer Stem Cells (CSCs) lysates induce antitumor immune killing effect in vitro. PLoS One 2014; 9: e114581.
105. Munz M, Baeuerle PA, Gires O,. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627-5629.
106. Cioffi M, Dorado J, Baeuerle PA, et al., EpCAM/CD3-Bispecific T-cell engaging antibody MT110 eliminates primary human pancreatic cancer stem cells. Clin Cancer Res 2012; 18: 465-474.
107. Cioffi M, Trabulo S, Hidalgo M, et al., Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin Cancer Res 2015; 21: 2325-2337.
108. Abate-Daga D, Lagisetty KH, Tran E, et al., A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. Hum Gene Ther 2014; 25: 1003-1012.
109. Anurathapan U, Chan RC, Hindi HF, et al., Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 2014; 22: 623-633.
110. Chmielewski M, Hahn O, Rappl G, et al., T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 2012; 143: 1095-1107 e1092.
111. Maliar A, Servais C, Waks T, et al., Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice. Gastroenterology 2012; 143: 1375-1384.